Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus.
HH is caused by a lack of hormones that normally stimulate the ovaries or testes. These hormones include gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH).
- The hypothalamus in the brain releases GnRH.
- This hormone stimulates the pituitary gland to release FSH and LH.
- These hormones tell the female ovaries or the male testes to release hormones that lead to normal sexual development in puberty, normal menstrual cycles, estrogen levels and fertility in adult women, and normal testosterone production and sperm production in adult men.
- Any change in this hormone release chain causes a lack of sex hormones. This prevents normal sexual maturity in children and normal function of the testicles or ovaries in adults.
There are several causes of HH:
- Damage to the pituitary gland or hypothalamus from surgery, injury, tumor, infection, or radiation
- Genetic defects
- High doses or long-term use of opioid or steroid (glucocorticoid) medicines
- High prolactin level (a hormone released by the pituitary)
- Severe stress
- Nutritional problems (both rapid weight gain or weight loss)
- Long-term (chronic) medical diseases, including chronic inflammation or infections
- Drug use, such as heroin or use or abuse of prescription opiate medicines
- Certain medical conditions, such as iron overload
Kallmann syndrome is an inherited form of HH. Some people with this condition also have anosmia (loss of the sense of smell).
- Lack of development at puberty (development may be very late or incomplete)
- In girls, a lack of breast development and menstrual periods
- In boys, no development of sex characteristics, such as enlargement of the testes and penis, deepening of the voice, and facial hair
- Inability to smell (in some cases)
- Short stature (in some cases)
- Loss of interest in sex (libido) in men
- Loss of menstrual periods (amenorrhea) in women
- Decreased energy and interest in activities
- Loss of muscle mass in men
- Weight gain
- Mood changes
Exams and Tests
The health care provider will perform a physical exam and ask about your symptoms.
Tests that may be done include:
- Blood tests to measure hormone levels such as FSH, LH, and TSH, prolactin, testosterone and estradiol
- LH response to GnRH
- MRI of the pituitary gland/hypothalamus (to look for a tumor or other growth)
- Genetic testing
- Blood tests to check for iron level
Treatment depends on the source of the problem, but may involve:
- Injections of testosterone (in males)
- Slow-release testosterone skin patch (in males)
- Testosterone gels (in males)
- Estrogen and progesterone pills or skin patches (in females)
- GnRH injections
- HCG injections
The right hormone treatment will cause puberty to start in children and may restore fertility in adults. If the condition begins after puberty or in adulthood, symptoms will often improve with treatment.
Health problems that may result from HH include:
- Delayed puberty
- Early menopause (in females)
- Low bone density and fractures later in life
- Low self-esteem due to late start of puberty (emotional support may be helpful)
- Sexual problems, such as low libido
When to Contact a Medical Professional
Call your provider if:
- Your child does not start puberty at the appropriate time.
- You are a woman under age 40 and your menstrual cycles stop.
- You have lost armpit or pubic hair.
- You are a man and you have decreased interest in sex.
Gonadotropin deficiency; Secondary hypogonadism
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364 www.ncbi.nlm.nih.gov/pubmed/29562364.
Styne DM, Grumbach MM. Physiology and disorders of puberty. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook of Endocrinology. 13th ed. Philadelphia, PA: Elsevier; 2016:chap 25.
White PC. Sexual development and identity. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 220.
Review Date 7/16/2019
Updated by: Brent Wisse, MD, board certified in Metabolism/Endocrinology, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.